Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.4.0.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Operating Activities:    
Net loss $ (3,707) $ (4,517)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on warrants [note 4 and note 5 [f]] (667) (465)
Depreciation 56 46
Stock-based compensation [note 5 [c] and note 5 [d]] 468 516
Changes in operating assets and liabilities:    
Interest receivable 58 42
Amounts receivable (219) 4,117
Prepaid expenses and other assets 401 (842)
Accounts payable (751) 916
Accrued liabilities other 268 (1,849)
Accrued clinical liabilities (1,516) (3,797)
Accrued compensation (523) (602)
Restricted cash   61
Excess lease liability   (194)
Lease obligation (14) 124
Deferred collaboration revenue [Note 3] (2,941)  
Net cash (used in) operating activities (9,087) (6,444)
Financing Activities:    
Taxes paid related to net share settlement of equity awards   (52)
Net cash (used in) provided by financing activities   (52)
Investing Activities:    
Purchase of investments (24,169) 1,071
Proceeds from maturities of investments 17,859 3,011
Purchase of property and equipment   (205)
Net cash (used in) provided by investing activities (6,310) 3,877
Net increase in cash and cash equivalents (15,397) (2,619)
Cash and cash equivalents at beginning of period 34,310 27,897
Cash and cash equivalents at end of period $ 18,913 $ 25,278